Willemijn F E Kuper1, Claudia van Alfen1, Linda van Eck1, Barbara C H Huijgen1, Edward E S Nieuwenhuis1, Marco van Brussel1, Peter M van Hasselt2. 1. From the Departments of Metabolic Diseases (W.F.E.K., P.M.v.H.), Pediatric Gastroenterology (E.E.S.N.), and Medical Physiology, Child Development and Exercise Center (M.v.B.), Wilhelmina Children's Hospital, University Medical Center Utrecht; Bartiméus Institute for the Visually Impaired (C.v.A., L.v.E.), Zeist and Doorn; and Center for Human Movement Sciences (B.C.H.H.), University Medical Center Groningen, University of Groningen, the Netherlands. 2. From the Departments of Metabolic Diseases (W.F.E.K., P.M.v.H.), Pediatric Gastroenterology (E.E.S.N.), and Medical Physiology, Child Development and Exercise Center (M.v.B.), Wilhelmina Children's Hospital, University Medical Center Utrecht; Bartiméus Institute for the Visually Impaired (C.v.A., L.v.E.), Zeist and Doorn; and Center for Human Movement Sciences (B.C.H.H.), University Medical Center Groningen, University of Groningen, the Netherlands. p.vanhasselt@umcutrecht.nl.
Abstract
OBJECTIVE: To delineate timing of motor decline in CLN3 disease. METHODS: Motor function, assessed by the 6-Minute Walk Test (6MWT), was evaluated repeatedly in 15 patients with CLN3 disease, resulting in 65 test results and during one occasion in 2 control cohorts. One control cohort (n = 14) had isolated visual impairment; a second cohort (n = 12) exhibited visual impairment in combination with neurologic impairments. Based on 6MWT reference values in healthy sighted children, z scores of 6MWT results in patients with CLN3 disease and control cohort individuals were calculated. 6MWT results were correlated with age-including multilevel modeling analysis allowing assessment of imbalanced repeated measurements-and with Unified Batten Disease Rating Scale (UBDRS) scores. RESULTS: In CLN3 disease, 6MWT scores were already impaired from first testing near diagnosis (mean z scores of -3.6 and -4.7 at 7 and 8 years of age, respectively). Afterwards, 6MWT scores continuously declined with age (r = -0.64, p < 0.0001) and with increasing UBDRS scores (r = -0.60, p = 0.0001), confirming correlation with disease progression. The decrease was more pronounced at a later age, as shown by the nonlinear multilevel model for 6MWT results in CLN3 disease (y = 409.18 - [0.52 × age2]). In contrast, an upward trend of 6MWT scores with age was observed in the control cohort with isolated visual impairment (r = 0.56; p = 0.04) similar to healthy, sighted children. The control cohort with additional neurologic impairments displayed a slightly decreased 6MWT walking distance independent of age. CONCLUSIONS: The 6MWT unveils early onset of motor decline in CLN3 disease.
OBJECTIVE: To delineate timing of motor decline in CLN3 disease. METHODS: Motor function, assessed by the 6-Minute Walk Test (6MWT), was evaluated repeatedly in 15 patients with CLN3 disease, resulting in 65 test results and during one occasion in 2 control cohorts. One control cohort (n = 14) had isolated visual impairment; a second cohort (n = 12) exhibited visual impairment in combination with neurologic impairments. Based on 6MWT reference values in healthy sighted children, z scores of 6MWT results in patients with CLN3 disease and control cohort individuals were calculated. 6MWT results were correlated with age-including multilevel modeling analysis allowing assessment of imbalanced repeated measurements-and with Unified Batten Disease Rating Scale (UBDRS) scores. RESULTS: In CLN3 disease, 6MWT scores were already impaired from first testing near diagnosis (mean z scores of -3.6 and -4.7 at 7 and 8 years of age, respectively). Afterwards, 6MWT scores continuously declined with age (r = -0.64, p < 0.0001) and with increasing UBDRS scores (r = -0.60, p = 0.0001), confirming correlation with disease progression. The decrease was more pronounced at a later age, as shown by the nonlinear multilevel model for 6MWT results in CLN3 disease (y = 409.18 - [0.52 × age2]). In contrast, an upward trend of 6MWT scores with age was observed in the control cohort with isolated visual impairment (r = 0.56; p = 0.04) similar to healthy, sighted children. The control cohort with additional neurologic impairments displayed a slightly decreased 6MWT walking distance independent of age. CONCLUSIONS: The 6MWT unveils early onset of motor decline in CLN3 disease.
Authors: An N Dang Do; Audrey E Thurm; Cristan A Farmer; Ariane G Soldatos; Colby E Chlebowski; Julie K O'Reilly; Forbes D Porter Journal: Am J Med Genet A Date: 2021-12-16 Impact factor: 2.578
Authors: Willemijn F E Kuper; Marlies Oostendorp; Brigitte T A van den Broek; Karin van Veghel; Lourens J P Nonkes; Edward E S Nieuwenhuis; Sabine A Fuchs; Tineke Veenendaal; Judith Klumperman; Albert Huisman; Stefan Nierkens; Peter M van Hasselt Journal: JIMD Rep Date: 2020-06-02
Authors: Aline K Honingh; Yvonne L Kruithof; Willemijn F E Kuper; Peter M van Hasselt; Paula S Sterkenburg Journal: Int J Environ Res Public Health Date: 2022-05-12 Impact factor: 4.614
Authors: Hanna Hildenbrand; Jordan Wickstrom; Rebecca Parks; Cris Zampieri; Thuy-Tien Nguyen; Audrey Thurm; Kisha Jenkins; Katharine E Alter; Jesse Matsubara; Dylan Hammond; Ariane Soldatos; Forbes D Porter; An N Dang Do Journal: Am J Med Genet A Date: 2021-02-08 Impact factor: 2.578
Authors: Willemijn F E Kuper; Claudia van Alfen; Linda van Eck; Stella A de Man; Marjolein H Willemsen; Koen L I van Gassen; Monique Losekoot; Peter M van Hasselt Journal: JIMD Rep Date: 2020-02-07